{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete Response"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Partial Response"},{"measurements":[{"groupId":"OG000","value":"18"}],"title":"Stable Disease"},{"measurements":[{"groupId":"OG000","value":"13"}],"title":"Progressive Disease"},{"measurements":[{"groupId":"OG000","value":"6"}],"title":"Inevaluable"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"}],"units":"Participants"}],"description":"The modified Response Evaluation Criteria in Solid tumors (RECIST) criteria was used for objective tumor response assessment. Complete Response (CR): Disappearance all target lesions; Partial Response (PR): \\>30% decrease in sum longest diameter (LD) of target lesions, reference baseline sum LD; Progressive Disease (PD): \\>20% increase in sum LD of target lesions, reference smallest sum LD recorded since treatment started or appearance of one or \\> new lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, reference smallest sum LD since treatment started. Response rate estimated by Gehan's Phase II clinical trial design.","groups":[{"description":"Gefitinib 250 mg daily by mouth until progressive disease, unacceptable toxicity or patient withdrawal.","id":"OG000","title":"Gefitinib"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Every 4 weeks until progressive disease, unacceptable toxicity or patient withdrawal","title":"Response Rate of ZD1839 in Patients With Advanced or Recurrent Salivary Gland Cancer Who Are Not Candidate for Curative Surgery or Radiotherapy","type":"PRIMARY","unitOfMeasure":"Participants"}